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It has been known for many years that 
the immune system can actively respond 
to (pre)neoplastic cells and prevent 
oncogenesis (a concept known as cancer 
immunosurveillance).1 However, in most 
cases, antitumor immune responses are 
inefficient and neoplasms are allowed to 
establish. Indeed, effector T cells often 
infiltrate developing malignant lesions and 
may significantly influence the prognosis 
of the disease,2,3 but are frequently 
functionally impaired.4 As compared with 
circulating T cells or T cells infiltrating 
healthy tissues, these cells (1) secrete 
reduced amounts of effector cytokines, 
(2) exhibit limited proliferative capacity, 
(3) express low levels of pro-survival 
receptors, and (4) display a terminally 
differentiated phenotype. Multiple 
mechanisms have been associated such a 
functional impairment, most of which can 
be reconducted to the immunosuppressive 
nature of the tumor microenvironment.5 
Malignant cells actively secrete cytokines, 
metabolites and other molecules that 
directly inhibit the function of antitumor 
T lymphocytes. In addition, cancer cells 
can recruit immune cell populations 
that are capable of hindering effector 
responses. These include, among others, 
CD4+CD25+FOXP3+ regulatory T cells 
and myeloid-derived suppressor cells, 
which mediate immunosuppressive 
effects via contact-dependent as well 
as contact-independent mechanisms.5 
Thus, neoplastic cells as well as 
immunosuppressive cells of the immune 
system express multiple inhibitory ligands 
on their surface that engage cognate 
receptors on T lymphocytes.
The CD28 family of co-receptors 
plays a major role in the regulation 
of immune responses, mostly as they 
deliver co-stimulatory or co-inhibitory 
signals to T-cells that have recognized a 
peptide/MHC complex on the surface 
of an antigen-presenting cell (APC).6 
Besides CD28, which operates as a major 
co-stimulatory receptor upon binding to 
CD80 (also known as B7-H1) or CD86 
(also known as B7-H2) on APCs, this 
family include cytotoxic T lymphocyte-
associated protein 4 (CTLA4) and 
programmed cell death 1 (PDCD1, 
commonly known as PD-1). CTLA-4, 
which also interacts with CD80 and CD86, 
is expressed on the surface of activated 
T cells (including Tregs) and delivers 
co-inhibitory signals. Along similar lines, 
upon interaction with its main ligands 
(CD274, also known as PD-L1, and 
PDCD1LG2), PD-1 negatively regulates 
multiple T-cell functions, including their 
activation, proliferative potential and 
ability to secrete effector cytokines. The 
most prominent physiological role of these 
molecules is to limit T-cell responses and 
avoid autoimmune diseases.6 However, the 
elevated expression levels of CTLA4 and 
PD-1 on cancer cells led to the hypothesis 
that these factors could underlie a major 
mechanism of immune escape mediated by 
the inhibition of effector T-cell responses.7
Chronic antigenic or inflammatory 
stimulation induces the expression of 
CTLA4 and PD-1 on the surface of 
T cells, as demonstrated in individuals 
chronically infected with HIV-1 and the 
hepatitis C virus (HCV).8 Similarly, these 
receptors are highly upregulated by tumor 
antigen-specific T cells, resulting in the 
robust impairment of effector functions. 
In line with this notion, the blockade 
of CTLA4 and PD-1 with specific 
monoclonal antibodies has been shown 
to promote tumor regression in multiple 
preclinical models as it stimulates 
the function of tumor-specific CD4+ 
and CD8+ T cells.7 CTLA4-targeting 
interventions also boost immune 
responses by simultaneously interfering 
with the inhibitory activity of Tregs.7 
These data strongly suggested that the 
blockade of CTLA4 and/or PD-1 could 
offer a valid approach for the treatment of 
a wide variety of cancers.9
Monoclonal antibodies are nowadays 
widely employed in anticancer 
immunotherapy.10,11 In 2 clinical trials 
published in June 2012, 2 different 
monoclonal antibodies targeting 
PD-1 or PD-L1 were given to patients 
affected by different solid tumors, 
including neoplasms that are generally 
refractory to immunotherapy such as 
lung carcinoma.12,13 Both antibodies 
exhibited significant clinical activity as 
they induced tumor regression (objective 
response rate of 18–27% and 6–17% for 
PD-1- and PD-L1-targeting antibodies, 
respectively) or stabilized disease 
progression. Importantly, none of the 
patients with PD-L1− tumors receiving 
anti-PD-1 antibodies manifested an 
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objective response, suggesting that the 
expression of PD-L1 on the surface of 
cancer cells constitutes a robust predictive 
biomarker that may allow clinicians 
to implement personalized therapeutic 
approaches.13
In a recent Phase I clinical trial, 
melanoma patients were treated with the 
hitherto experimental anti-PD-1 antibody 
nivolumab plus ipilimumab, a CTLA4-
blocking antibody approved by US 
Food and Drug Administration (FDA) 
for use in this oncological indication in 
2011.14 The authors reported an objective 
response rate of 40% and evidence of 
clinical activity in 65% of the patients. In 
spite of the fact that up to 53% of patients 
experienced Grade III-IV adverse events 
(although reversible, for the vast majority), 
some degree of tumor regression could be 
observed in more than 80% of cases.
These results lend strong support to 
the notion that the dormant immune 
system can be awaken by the simultaneous 
inhibition of distinct immunological 
checkpoints. High-content single-cell 
analysis of the phenotype and functionality 
of the immune cell subpopulations 
involved in such a reactivation will 
provide further insights into the effector 
mechanisms that mediate cancer 
immunosurveillance in humans. Given 
the large number of functions regulated 
by CTLA4 and PD-1, these mechanisms 
are likely to involve multiple cell types. 
Currently, a number of biological agents 
including immunostimulatory cytokines 
such as interleukin-15,15 are being tested 
to break the immunological tolerance 
of cancer patients and boost antitumor 
T-cell immunity. As it has already been 
demonstrated in preclinical settings,16 
the combination of immunostimulatory 
agents with checkpoint inhibitors may 
boost even further anticancer immune 
responses and hence constitute an optimal 
immunotherapeutic approach against (at 
least some types of) cancer.
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